Bristol-Myers Squibb Company (BMY) Receives Positive Decision From National Institute for Clinical Excellence (NICE) for YERVOY® (ipilimumab)  
11/2/2012 8:23:19 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY® (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD). This important decision will enable eligible patients in England and Wales to routinely access treatment with YERVOY through the National Health Services (NHS).